Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137297 | 0.93 | USP2 (0.55) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL893656 | 0.87 | ESR2 (0.47) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1063509 | 0.83 | ESR2 (0.52) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL24536622 | 0.82 | HPGD (0.48) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL157123 | 0.81 | HPGD (0.50) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4181120 | 0.81 | USP2 (0.53) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL16925538 | 0.81 | HPGD (0.50) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14408021 | 0.80 | HPGD (0.49) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| Formaldehyde SCHEMBL27903154 | 0.80 | HPGD (0.64) | HPGDUSP2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7858182 | 0.80 | HPGD (0.68) | HPGDUSP2SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100394-B1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-11 | — | — | US | disclosed |
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-09-04 | — | — | US | disclosed |
| WO-2025077770-A1 | FUSED RING COMPOUND AND USE THEREOF IN KRAS INHIBITOR | 成都海博为药业有限公司 | 2025-04-17 | — | — | WO | disclosed |
| US-20250092018-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-03-18 | — | — | US | disclosed |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2024-12-24 | — | — | US | disclosed |
| US-12152015-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| WO-2024148029-A2 | ORGANIC COMPOUNDS AS NLRP3 INHIBITORS | KODIAK SCIENCES INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-100544719-C | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | MORPHOCHEM AG (DE) | 2009-09-30 | — | — | CN | disclosed |
| EP-1709044-B1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1620098-B1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20080027040-A1 | Oxazolidinone-Quinolone Hybrid Antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-07-05 | — | — | US | disclosed |
| EP-1709044-A2 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2006-10-11 | — | — | EP | disclosed |
| CN-1832746-A | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | MORPHOCHEM AG KOMB CHEMIE (DE) | 2006-09-13 | — | — | CN | disclosed |
| EP-1620098-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005058888-A2 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2005-06-30 | — | — | WO | disclosed |
| WO-2004096221-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | HPGD 1030/4885USP2 4303/4885SMN1; SMN2 564/4885 |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | HPGD 1030/4885USP2 4303/4885SMN1; SMN2 564/4885 |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | HPGD 1030/4885USP2 4303/4885SMN1; SMN2 564/4885 |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | OXA1L, ANTXR2, AAAS | HPGD 213/4885USP2 3402/4885SMN1; SMN2 4238/4885 |
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | HBZ, ZFX, WIZ | HPGD 1767/4885USP2 3987/4885SMN1; SMN2 390/4885 |
| US-20250092018-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PDE7A | HPGD 440/4885USP2 1526/4885SMN1; SMN2 2271/4885 |
| US-20080027040-A1 | Oxazolidinone-Quinolone Hybrid Antibiotics | OXA1L, TOP1, TOP2A | HPGD 278/4885USP2 3130/4885SMN1; SMN2 4448/4885 |
| US-12152015-B2 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof | ENPP1, ENPP3, PPA1 | HPGD 393/4885USP2 1537/4885SMN1; SMN2 2933/4885 |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | HPGD 1030/4885USP2 4303/4885SMN1; SMN2 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.